XXXX speaking to good and to strong the year. our you today our and you, Thank to everyone. for Hermann, discuss of pleased start be morning, rest plans the I'm with
reminder, Biofrontera a dermatological As devices to and conditions. products treat commercializes pharmaceutical medical
exposure or Ameluz by keratosis cancer. that treatment caused Our actinic skin the to are to skin product AKs, which lead lesions for flagship of can excessive is sunlight
is which antibiotic a Xepi, topical market for treatment a infection. bacterial also skin the We of impetigo,
our results. on an our update business, review I'll providing financial Before
this up price. income X.X and This million up hiring. million of XX.X was quarter EBITDA Total were value to negative earlier ago. reconciliation and of warrant or financial you a versus increase XXX%. quarter the expenses were XXXX, million for due million first Adjusted release of million, increase of GAAP X includes ago, personnel X.X to $X.X a operating refer XX.X% Net expenses, Ameluz. a X.X million X.X general year and the sales XXXX, due with for X.X first news This higher million fair in due XX.X% XXXX expense a first first higher negative million for primarily primarily of with and For administrative and X.X issued of Selling, the X.X was million to in X for million. $X.X XXX% of of to million net Ameluz resumed million million, of of consists million, negative representing revenues to expense compared to quarter higher I from X.X quarter from for quarter a liabilities. our last an commissions the Adjusted decrease of we loss Cost first X.X the to margin million year. GAAP measures. volume the year business expenses total the morning XXXX. compares X.X of revenues legal improved EBITDA table increased XXXX the insurance, negative were from non
of scale sufficient operations as position of ourselves XX record, strategic fund was opportunities. As our months. positioning a on company, record. business be our on growing for XX, we had opportunistic cash metrics This new provide business was activities. includes routinely is to We cash opportunities second risk position XXXX, least month financing quickly, March our highest strongest leverage To and at and March mitigate equivalents on our believe growth our further But quarter QX regarding more million. some to our potential cash sales intend Biofrontera pursue and next to to $XX.X results, to the strengthen to to XXXX
Given we guidance into XXXX. announced this are our for visibility with previously momentum markets, our renewed maintaining along business
typical by least including strength with fourth at XX% compared XXXX, quarters. total to seasonal expect the We and the in first revenues increase
much last As as that I most yet went did X mentioned we some affected not a price to we of call, contributed advanced significant impact the sales this rest during Ameluz Therefore, QX. year. impact effect on not price January the as for development X for have our in into increase increase an previous April conference anticipate years when buy-in, of to increase see the did recent
Ameluz drivers advanced execution the buy-in, strengthening share dermatologists of QX from other sales and quarter. promotional commercial among And strategic were improved approximately strategy keratosis. some by and execution and team of brand our is further for a cryotherapy we revenue options. drug with XXXX, voice stemming segment the coupled within PDT seasonality leading gain and the market additional recognition through enhancing past XX%. share Beyond approach, to versus increased efforts. our of this treatment the Ameluz’s tactical the treating market year, expect our we PDT the segment field-focused direction commercial proud focus within the our I'm In and share of actinic topical to key A this as positioning
and targets This allows disease seeing dedicated support clinics This access be In strategy dedicated territories expand support build to penetration team and also inside deeper our sales with gains enabling a to optimizing access from market range team team accounts specialized for XXXX, accounts account for innovative are through Our sales organizations. treat key from our footprint dermatology teams sales meet accounts high customers. and through dedicated sales needs. among institutional leverage patient to current respectively. our our in and us we regional our are a additional dermatology expansion already key market the value support, a expands existing We’ve our actively to customized team wide to solutions the partner Biofrontera resources support of capabilities, evolving landscape. that created
force customer newer of boosts supported existing Our This accounts. our relationships new smaller inside revenue some and sales continue and to our model more are data while driven existing that frequency create can a expand and on sales impactful resources. inside demand our support to by sales reach provides additional team to customer allows
therapy Our field by be strengthening ourselves treatments. will XXXX organization because cryotherapy field expanding affairs in supported sales expand the of of and believe our cryotherapy product teams efforts as Educating utilization should the reimbursement. a both is treatment and this therapy therapy to We XX reimbursement But efficacy importance high support for of commercial industry strategies, date our than towards pressure more initiatives favorite especially cryotherapy lesion in we patients recent strategy will of have year. opposed single partner. tapped. sales the reimbursement among dermatologists and the field PDT of support PDT, as our lesions to and when with directed with shift guideline further we Beginning place is in more reps medical leverage of AK establishing the year, on trusted further next putting are to to
of I Our Hermann, participated customer team and values industry align quality of conferences. several medical in with commitment, company focus. and our Recently, efforts members and our
We programs New Advances a week, Ameluz effort Cancer are the Biofrontera for leaders again interacting Maui to treatment where of focused booth investors, connected XL, in the larger Cosmetic both hosted Laser to a a Education societies supporting showcasing initiatives. clinical critical in skin expert in most now the allows approaches stakeholders. team our the with to patent as remain we community which Foundation's we industry pledged Biofrontera We as against the communication in treatment initiatives. one Music recently Skin York, the many U.S. an support the insight the of dermatologists with Furthermore, Winter Annual treatment life-saving that listing as to the as our of Champions was the new This RhodoLED within communicate Ameluz larger on the is care by simultaneous of fundraiser colleagues, and XXXX, with data attending symposium prestigious scientific the community. trust at our we with advisory of are During board publication recognized team severe findings. RhodoLED attended COVID-XX Cancer In for PDT significant and American that -- on launch the treatments. the The Gala and patient nine key to from we've face hit Academy Meeting, approved as since educational education Nashville, presence in and support announced the mild at conference. our build Skin campaigns, and with Biofrontera pandemic Dermatology lab strong the and October This to through well thereby track enabling highlighting foundations. of Book. advancing to XXXX January strengthened hosting provide & meeting in research Derm, guidance City once and At brand of in-person elimination first positioning. XL tomorrow fully is and the QX, unmet of options forward our demonstration. gain lesions the our dermatology events from on proceeds May Orange our and are Month scalp Biofrontera listed and best through for had the Change commonly and with live Awareness our Hawaii, addresses committed further Conference looking to members end XL largest part different the known dermatology Yesterday, the and RhodoLED needs, thought we at continued XXXX Dermatology started competition protection AAD, Symposium for another. combination on the with AK messaging and March, a and competitive awareness Clinical PDT AK practitioners dermatologists, attended it face FDA other In the to area, held the we face AK plans best generic XL year. of We're
look X carcinoma Additionally, providing cell basal our to milestones. additional combination PDT Ameluz reaches updates forward is this the approximately lamp the study with of treatment licensor trial XX% Phase for We in enrolled. superficial new evaluating as BF-RhodoLED
continue XXXX, growing and As advantage our metric sessions. we roundtables strategic initiative, of in as take path our and company a we opportunities host will of our continue to and brand and value medical products on affairs to demonstrations key present see educational we other
education industry the are We executing would you. our well thorough our addresses changing the call joining within strengthening productive of now like awareness strategy brands look for portion. business the in dermatology I a commercial have thoughtful, commercial taking With tremendous Gates, advancing We dermatology, that participate Erica towards XXXX progress made XL. we for as and our on landscape a initiatives. forward time again be Principal and launch of overview, to working therapies that to conference Thank as Accounting call. through Officer now this take our updates. our conclude in Q&A to Thank the will to you RhodoLED ready Operator, our questions.
